ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Bliss GVS Pharma Ltd reported revenue from operations of ₹257 Cr (+29.8% YoY) and net profit of ₹37 Cr (+121.6% YoY) for Q4 FY26.
Bliss GVS Pharma reported audited standalone and consolidated financial results for the year ended March 31, 2026. The Board also recommended a 100% final dividend.
Bliss GVS Pharma granted 1,80,000 stock options at Rs. 43 per share. The options vest over four years, aligning employee interests with long-term shareholder value.
Bliss GVS Pharma announced successful postal ballot results for appointing two independent directors. Shareholders approved both special resolutions with overwhelming majorities via remote electronic voting.
Bliss GVS Pharma Limited has scheduled a board meeting for May 12, 2026, to consider audited financial results for the year ended March 2026 and recommend a final dividend. The trading window for designated persons is closed from April 1, 2026, until May 14, 2026.
Bliss GVS Pharma Ltd has scheduled a board meeting on May 12, 2026, to approve audited standalone and consolidated financial results for FY2026. The board will also consider recommending a final dividend. The trading window for designated persons remains closed until 48 hours after the results announcement.
Bliss GVS Pharma Limited has issued a Postal Ballot notice seeking shareholder approval for the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Independent Directors. Both appointments are for a five-year term effective from April 03, 2026. The e-voting period ends on May 09, 2026.
Bliss GVS Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Independent Directors for five-year terms. The e-voting period runs from April 10, 2026, to May 09, 2026, with results to be announced by May 12, 2026.
Bliss GVS Pharma Limited has been assigned a credit rating of [ICRA]A- (Stable) and [ICRA]A2+ by ICRA Limited for its bank facilities worth ₹100.00 Crore. This rating reflects the company's creditworthiness and stable financial outlook for its fund-based and non-fund-based instruments.